ASGR1 and familial amyloid neuropathy: Since the approval of the first lipid nanoparticle (LNP)–assisted siRNA therapeutics (patisiran) for the treatment of hATTR amyloidosis, three other siRNA therapeutics that are chemically modified with N-acetylgalactosamine (GalNAc) have been successfully developed for hepatocyte-targeting delivery by specifically binding with asialoglycoprotein receptor (ASGPR) on the cell surface (51).